Post-earnings recap
Reported
Mon, Oct 19, 2009
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
Boston Scientific's earnings report shows a solid EPS beat, which likely contributed to the 1.4% increase in stock price. The strong EPS performance indicates effective cost management and possibly strong demand in certain product areas. However, the lack of revenue data and guidance leaves some uncertainty about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.19 | N/A | +34.75% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a positive outlook regarding their product lines. However, they acknowledged the ongoing economic uncertainties.
Management highlighted strong performance in key product areas.
They expressed confidence in maintaining market position despite economic challenges.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—